Research Advances of m⁶A RNA Methylation in Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2020.102.35
- Author:
Hongli PAN
1
;
Xuebing LI
1
;
Chen CHEN
1
;
Yaguang FAN
1
;
Qinghua ZHOU
1
Author Information
1. Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute,
Tianjin Medical University General Hospital, Tianjin 300052, China.
- Publication Type:Journal Article
- Keywords:
Epigenetic modification;
Lung neoplasms;
N6-methyladenosine;
RNA methylation
- From:
Chinese Journal of Lung Cancer
2020;23(11):961-969
- CountryChina
- Language:Chinese
-
Abstract:
N6-methyladenosine is one of the most prevalent mRNA modification in eukaryotes. The regulation of this pervasive mark is a dynamic and reversible process. m⁶A RNA methylation is catalyzed by m⁶A writers, removed by m⁶A erasers and recognized by m⁶A readers, thereby regulating multiple RNA processes including alternative splicing, nuclear export, degradation and translation. Accumulated evidence suggests that m⁶A modification plays a crucial role in the pathogenic mechanism and malignant progression in non-small cell lung cancer (NSCLC), including cell survival, proliferation, migration, invasion, tumor metastasis and drug resistance. Moreover, the expression of m⁶A and its related proteins are dysregulated in clinical samples and circulating tumor cells (CTCs) of lung cancer patients, indicating that m⁶A modification may serve as a novel potential biomarker for the diagnosis and prognosis of lung cancer. In this review, by summarizing a great number of recent reports related to m⁶A's function and its modulators, we aim to provide a new insight on the early diagnosis and drug development in NSCLC therapy.
.
